
Gilead Partners with Indian Manufacturers on HIV Medicines
Gilead Sciences announced that it is entering into agreements with Indian generic drug manufacturers to enhance access in developing countries to its anti-HIV medicine, emtricitabine.
Gilead Sciences
Gilead says it has a longstanding commitment to make its antiretroviral products available at significantly reduced prices in developing countries. A key component of this commitment is nonexclusive, generic licensing agreements established with Indian manufacturers to produce and sell high-quality, low-cost versions of Gilead's HIV medicines. A total of 13 Indian companies now have licensed Gilead HIV medicines. According to John C. Martin, PhD, Gilead’s chairman and chief executive officer, “India’s pharmaceutical industry is a world leader in process chemistry, and our ongoing collaboration will be critical for furthering access to affordable, high-quality, first-line HIV treatment for developing countries.”
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.